Floatz logo

Tenofovir Alafenamide

Chronic Hepatitis B Virus Infection

Ningbo No.2 HospitalSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Chronic Hepatitis B Virus Infection cohort.

Asset / SponsorPhaseRating
Entecavir
Beijing Continent Pharmaceutical Co, Ltd.
Phase 4BBB
Lamivudine
Yonsei University
Phase 4BBB
Tenofovir Disoproxil Fumarate
Ningbo No.2 Hospital
Phase 4BBB
Telbivudine
The Fifth People's Hospital of Suzhou
Phase 4BBB
PEGYINTERFERON-ALFA-2A
Huashan Hospital
Phase 4BB

View all 25 →

Same molecule, other indications

Tenofovir Alafenamide is also rated in:

HIV infectious diseaseActive
BB
Indicative · Phase 4
71 / 100
View asset →
hepatocellular carcinomaActive
BB
Indicative · Phase 4
68 / 100
View asset →
hepatitis B virus infectionActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →